AcelRx Tries Transparency To Reassure Investors After Zalviso ‘Complete Response’
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Trying to beat The Medicines Co. to market with a patient-administered post-surgical pain analgesic, AcelRx hopes it can refile the NDA for Zalviso by the end of 2014, based on already-filed amendments and adjustments to the delivery mechanism and instructions for use.